Narrow search
Showing 1 - 6 of 6
Cover Image
Patient relevant endpoints in oncology: current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health Economics Review 4 (2014) 1, pp. 1-8
D61; H51; I18. </AbstractSection> Copyright Dabisch et al.; licensee Springer. 2014
Persistent link: https://www.econbiz.de/10010998823
Cover Image
Analysis of endpoints used in marketing authorisations versus value assessments of oncology medicines in Germany
Ruof, Jörg; Knoerzer, Dietrich; Dünne, Anja-Alexandra; … - In: Health Policy 118 (2014) 2, pp. 242-254
marketing authorisation to those considered by G-BA in the field of oncology. …
Persistent link: https://www.econbiz.de/10011116913
Cover Image
Patient relevant endpoints in oncology: Current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health Economics Review 4 (2014) 2, pp. 1-8
, focusing on overall survival as the preferred endpoint in oncology. A taskforce of experienced German outcomes research … external stakeholders. Distinctive features of registration trials in oncology need to be considered when these studies form … clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly …
Persistent link: https://www.econbiz.de/10011599811
Cover Image
Patient relevant endpoints in oncology : current issues in the context of early benefit assessment in Germany
Dabisch, Inna; Dethling, Jürgen; Dintsios, … - In: Health economics review 4 (2014) 2, pp. 1-8
, focusing on overall survival as the preferred endpoint in oncology. A taskforce of experienced German outcomes research … external stakeholders. Distinctive features of registration trials in oncology need to be considered when these studies form … clinical trial programs that were developed to be consistent with regulatory guidance, endpoints in oncology are thoroughly …
Persistent link: https://www.econbiz.de/10010528451
Cover Image
How Far is Germany From Value-Based Pricing 10 Years After the Introduction of AMNOG?
Dintsios, Charalabos-Markos; Chernyak, Nadja - In: Applied Health Economics and Health Policy 20 (2021) 3, pp. 287-290
Persistent link: https://www.econbiz.de/10014497506
Cover Image
Methodenvorschlag des IQWiG zur Kosten-Nutzen-Bewertung von medizinischen Verfahren
Koch, Klaus; Dintsios, Charalabos-Markos; Sawicki, Peter T. - In: Sozialer Fortschritt : unabhängige Zeitschrift für … 57 (2008) 12, pp. 294-300
Persistent link: https://www.econbiz.de/10003825134